Pharmaniaga Bhd 2025 SR
The report highlights Pharmaniaga's transition out of PN17 status and its focus on biopharmaceutical expansion, including the localization of insulin and vaccines. Key achievements in 2025 include improving its FTSE4Good ESG rating to 4.6 and achieving a 4-star rating. The company advanced its climate strategy by expanding Scope 3 reporting and installing solar PV systems across six sites, resulting in significant energy savings. Socially, the group maintained zero workplace fatalities and focused on human rights policy development and local supplier support, with 81% of procurement spend allocated locally.
Company: Pharmaniaga Bhd
Sector: Health Care
Country: Malaysia
Year: 2025
Type: SR
Pages: 69
Pharmaniaga Bhd
Sustainability Report
The report highlights Pharmaniaga's transition out of PN17 status and its focus on biopharmaceutical expansion, including the localization of insulin and vaccines. Key achievements in 2025 include improving its FTSE4Good ESG rating to 4.6 and achieving a 4-star rating. The company advanced its climate strategy by expanding Scope 3 reporting and installing solar PV systems across six sites, resulting in significant energy savings. Socially, the group maintained zero workplace fatalities and focused on human rights policy development and local supplier support, with 81% of procurement spend allocated locally.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees